The biotechnology industry continues to face a complex and rapidly changing marketplace. While there has been good news in recent years on some fronts, such as FDA approvals and US IPOs, companies must still focus on improving the efficiency of R&D in the face of limited resources. Meanwhile, payers are bringing more scrutiny to coverage decisions — making it imperative for companies to demonstrate how their products add value. In response to these trends, EY’s 2014 biotechnology industry report explores approaches that allow companies to “unlock value” by conducting R&D in ways that are both more capital-efficient and better aligned with the need to demonstrate value. Our point of view highlights three such approaches: precision medicine, adaptive trials and pre-commercial collaborations.
To learn more about these themes — and how the industry held up on key metrics related to financial performance, financing, M&A, strategic alliances, pipeline and products — stay tuned for Beyond borders 2014.
Sponsored by: EY
Open to Education and Exhibition Access, Convention Access, Convention Access & Partnering
Session ID: 2584